RenovoRx/$RNXT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About RenovoRx
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.
Ticker
$RNXT
Sector
Primary listing
Employees
10
Headquarters
Website
RenovoRx Metrics
BasicAdvanced
$34M
-
-$0.36
1.26
-
Price and volume
Market cap
$34M
Beta
1.26
52-week high
$1.45
52-week low
$0.75
Average daily volume
195K
Financial strength
Current ratio
8.609
Quick ratio
8.147
Long term debt to equity
1.513
Total debt to equity
2.443
Profitability
Gross margin (TTM)
62.84%
Net profit margin (TTM)
-1,610.88%
Operating margin (TTM)
-1,699.09%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-54.82%
Return on equity (TTM)
-107.11%
Valuation
Price to revenue (TTM)
41.935
Price to book
3.24
Price to tangible book (TTM)
3.24
Price to free cash flow (TTM)
-2.69
Free cash flow yield (TTM)
-37.18%
Free cash flow per share (TTM)
-0.35
Growth
Earnings per share change (TTM)
-32.77%
3-year earnings per share growth (CAGR)
-31.02%
RenovoRx News
AllArticlesVideos
RenovoRx CEO Shaun Bagai to Present at H.C. Wainwright's 27th Annual Global Investment Conference in New York City, September 8-10, 2025
Business Wire·6 days ago
RenovoRx Launches Multi-Center Post-Marketing Registry Study to Evaluate Cancer Treatment Delivered by RenovoCath® Device to Solid Tumors
Business Wire·4 weeks ago
RenovoRx to Host Second Quarter 2025 Financial Results and Business Highlights Conference Call on August 14th at 4:30 p.m. ET
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for RenovoRx stock?
RenovoRx (RNXT) has a market cap of $34M as of August 26, 2025.
What is the P/E ratio for RenovoRx stock?
The price to earnings (P/E) ratio for RenovoRx (RNXT) stock is 0 as of August 26, 2025.
Does RenovoRx stock pay dividends?
No, RenovoRx (RNXT) stock does not pay dividends to its shareholders as of August 26, 2025.
When is the next RenovoRx dividend payment date?
RenovoRx (RNXT) stock does not pay dividends to its shareholders.
What is the beta indicator for RenovoRx?
RenovoRx (RNXT) has a beta rating of 1.26. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.